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Background: We developed and validated an integrated radiomic-clinicopathologic nomogram (RadClip) for
post-surgical biochemical recurrence free survival (bRFS) and adverse pathology (AP) prediction in men with
prostate cancer (PCa). RadClip was further compared against extant prognostics tools like CAPRA and Decipher.
Methods: A retrospective study of 198 patients with PCa from four institutions who underwent pre-operative
3 Tesla MRI followed by radical prostatectomy, between 2009 and 2017 with a median 35-month follow-up
was performed. Radiomic features were extracted from prostate cancer regions on bi-parametric magnetic
resonance imaging (bpMRI). Cox Proportional-Hazards (CPH) model warped with minimum redundancy
maximum relevance (MRMR) feature selection was employed to select bpMRI radiomic features for bRFS pre-
diction in the training set (D1, N = 71). In addition, a bpMRI radiomic risk score (RadS) and associated nomo-
gram, RadClip, were constructed in D1 and then compared against the Decipher, pre-operative (CAPRA), and
post-operative (CAPRA-S) nomograms for bRFS and AP prediction in the testing set (D2, N = 127).
Findings: “RadClip yielded a higher C-index (0.77, 95% CI 0.65-0.88) compared to CAPRA (0.68, 95% CI 0.57-
0.8) and Decipher (0.51, 95% CI 0.33-0.69) and was found to be comparable to CAPRA-S (0.75, 95% CI 0.65-
0.85). RadClip resulted in a higher AUC (0.71, 95% CI 0.62-0.81) for predicting AP compared to Decipher (0.66,
95% CI 0.56-0.77) and CAPRA (0.69, 95% CI 0.59-0.79).”
Interpretation: RadClip was more prognostic of bRFS and AP compared to Decipher and CAPRA. It could help
pre-operatively identify PCa patients at low risk of biochemical recurrence and AP and who therefore might
defer additional therapy.
Funding: The National Institutes of Health, the U.S. Department of Veterans Affairs, and the Department of Defense.
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Research in Context
Evidence before this study
Prostate cancer (PCa) is the most common cancer among men.
Approximately 20 to 40 percent of patients experience biochemi-
cal recurrence (BCR) following definitive therapy, and may fur-
ther develop metastasis. Several tools, such as the Prostate
Cancer Risk Assessment (CAPRA) score, Post-surgery Prostate
Cancer Risk Assessment (CAPRA-S) score, and Decipher genomic
test, have been proposed to identify patients who are at risk of
developing BCR or adverse pathology (AP). AP is known to be
strongly associated with risk of BCR and metastasis. Recently,
radiomic features derived from bi-parametric magnetic reso-
nance imaging (bpMRI) have been shown to capture sub-visual
texture patterns for quantitative characterization of tumors phe-
notypes, and radiomic classifiers have been shown to aid in PCa
risk stratification. Integrating pre-operative bpMRI derived radio-
mic parameters with clinicopathologic parameters may allow for
even better prognostication of AP and PCa-specific outcome.
Added value of this study
In this study, we developed a prognostic nomogram, RadClip,
and incorporated radiomic features extracted from bpMRI with
pre-operative clinicopathologic parameters. Following an inde-
pendent, multisite validation, we found that pre-operative Rad-
Clip was more prognostic of BCR and AP compared to Decipher
and CAPRA for PCa patients who had undergone radical
prostatectomy.
Implications of all the available evidence
The radiomic nomogram presented in this study could be
potentially used as a surrogate to genomic-based prognostic
tests to identify PCa patients with low risk of BCR and AP and
who therefore might defer additional therapy.
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Radical prostatectomy (RP) is one of the primary treatments for
localized prostate cancer (PCa) [1]. However, approximately 20% to
40% of patients experience biochemical recurrence (BCR) who may
further develop metastasis after definitive treatment [24]. In addi-
tion, it has been shown that 25% of patients with low PCa volume and
biopsy Gleason Grade Group (GG) 2 harbor adverse pathology (AP)
[5], which is known to be a predictor for developing BCR and subse-
quent metastasis [6,7], and thus indicates exclusion of active surveil-
lance [8].
Several tools have been proposed to identify patients at risk of
presence of AP at final pathology [8], developing BCR [9,10], and sub-
sequent metastasis [911]. These have included pre-operative tools,
such as Prostate Cancer Risk Assessment (CAPRA) score, which was
used to predict AP, risk of BCR and metastasis, and prostate cancer-
specific survival [10]; and post-operative tools like Post-surgery
Prostate Cancer Risk Assessment (CAPRA-S) score, which was devel-
oped to predict risk of BCR and metastasis after RP [9]. These assess-
ments integrate factors, such as prostatespecific antigen (PSA), GG,
surgical margin (SM) status, extracapsular extension (EPE), seminal
vesicle invasion (SVI), and lymph node involvement (LNI), which
have been previously shown to be significantly associated with risk
of BCR [9]. However, these tools based on clinicopathological features
failed to account for tumor molecular heterogeneity and their perfor-
mance varies between different cohorts. In the last decade, there has
been heightened interest in exploring the utility of different genomicsignatures in predicting oncological outcomes after RP; the most uti-
lized test in the real world practice is Decipher which has been
shown to correlate with increased cumulative incidence of BCR,
metastasis and PCa-specific mortality [12].
Pre-operative multi-parametric magnetic resonance imaging
(mpMRI) has been utilized to help in PCa diagnosis [13], planning for
surgery [14] and to predict the presence of AP, e.g. SVI [15] and EPE
[16]. Recently, mpMRI radiomic derived features have shown to cap-
ture of sub-visual texture patterns for quantitative characterization
of tumors phenotypes, and help in PCa risk stratification [1720].
Integrating pre-operative mpMRI derived radiomic parameters with
clinicopathologic parameters may allow for even better prognostica-
tion of AP and PCa specific outcome.
In this study, we sought to develop and evaluate a radiomic risk
score (RadS) derived from bi-parametric MRI (bpMRI), including T2-
weighted (T2WI) and Diffusion Weighted Imaging (DWI), for predic-
tion of biochemical recurrence free survival (bRFS) and AP. Addition-
ally, we also constructed a novel nomogram, RadClip, by integrating
RadS, pre-operative prostate-specific antigen (PSA) and biopsy GG.
RadClip was compared against the Decipher test, and the pre-opera-
tive CAPRA and post-operative CAPRA-S nomograms for bRFS and AP
prediction on a multi-site validation set.
Materials and methods
Ethics statement
This retrospective study was approved by the Case Western
Reserve University Institutional Review Board reviews (IRB) and was
compliant with the Health Insurance Portability and Accountability
Act (HIPAA); de-identified data were used, and no protected health
information was needed. The need for an informed consent from all
patients was waived by the IRB.
Patient selection
A total of 408 PCa patients from four institutions who had under-
gone pre-operative 3 Tesla (3T) prostate mpMRI between 2009 and
2017 were initially identified. Patients who met the following criteria
were selected: patients who had (1) undergone RP after the MRI;
(2) no history of neoadjuvant or adjuvant therapy; (3) images of ade-
quate quality; and (4) and follow up information which includes
postoperative serum PSA measurements (Fig. 1). Patients were
excluded if they (1) were without T2WI or Apparent Diffusion Coeffi-
cient (ADC) maps; (2) were of sub-optimal image quality, e.g. ADC
map distortion; (3) received radiation therapy (RT) as the definitive
treatment, due to the difference in definition of BCR between RP and
RT [24]; (4) were with PSA persistence; or (5) received additional
therapies before RP.
A total of 198 patients that met the above eligibility criteria with a
median follow-up of 35 months were identified, of these 106 men
also underwent the Decipher test on PCa tissue sampled from the
corresponding surgical specimen. (Table 1) 71 patients from a single
site comprised the training set (D1), the remaining patients com-
prised the independent test set (D2, N=127).
BCR was defined as 2 consecutive serum PSA > 0.2 ng/mL; bRFS
was defined as the interval between the date of RP and the date of
BCR [21]. Patients who were still alive without BCR at the last
reported follow-up or the date of additional therapy applied were
labeled as censored. AP was defined as the presence of SVI, EPE or LNI
on the surgical specimen.
MRI Protocol and prostate cancer delineations
All patients were imaged on 3T MRI scanners with either a surface
pelvic phased-array coil (PPAC) or an endorectal coil (ERC). All studies
Fig. 1. Flowchart of patient selection from four institutions. RT = radiation therapy; RP = radical prostatectomy; BCR = biochemical recurrence; mpMRI = multi-parametric magnetic
resonance imaging.
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minimum. (Table 2) The mpMRI scans were reviewed and PCa
regions were delineated on T2WI and ADC maps using the 3D Slicer
software [22] by experienced radiologists. (A.S.P, 10 years of experi-
ence; V.C.O, 4 years of experience, S.H.T, 7 years of experience; and B.
M 2 years of experience) The PCa delineations on MRI were made
either by referring to their corresponding RP specimen (N = 56), or
biopsy and pathology reports when RP specimens were not available
(N = 142). Only the index lesions, defined as tumor of highest GG
from each patient were included for radiomic analysis.
MRI pre-processing and radiomic analysis
Intensity drift artifacts across different MRI acquisitions cause
T2WI to lack in tissue-specific meaning. Therefore, a nonparametric
intensity standardization method [23] was used to align T2WI inten-
sity distributions. In addition, bias-field artifacts introduced by the
endorectal coil were corrected using a previously published method
in which the estimated bias field is subtracted from the acquired
image data [24]. Both T2WI and ADC maps were resampled to the
same spatial resolution in the axial plane (0.5 £ 0.5mm). After pre-
processing, 200 radiomic feature, including first and second order
statistics, Gabor [25], Laws [26], Haralick [27] and CoLlAGe features
[28], were extracted on a per-voxel basis within PCa lesion regions
on both T2WI and ADC maps. These features characterize the under-
lying texture, quantify heterogeneity on imaging, and have previ-
ously been shown to be promising in PCa characterization [17,29,30].
Statistics including mean, standard deviation, skewness, and kurtosis
were calculated for each voxel-wise radiomic feature to characterize
its distribution within each PCa lesion region.
Statistics
Feature selection and stability assessment. Highly correlated
(Pearson’s correlation coefficient (R) > 0.9) radiomic features were
first eliminated and unstable radiomic features were further
excluded using test-retest scans from the Quantitative Imaging Net-
work (QIN) [31]. This dataset involved test-retest 3T mpMRI scans of
15 subjects obtained over a period of 2 weeks using the same scannerwith PCa lesions annotated separately on each scan [31]. The ratio-
nale behind using these QIN cases was that stable radiomic features
should remain relatively consistent across the test-retest scans of the
same patient. Consequently, we only included stable radiomic fea-
tures which are identified as those without significant difference (p <
.05, Wilcoxon signed-rank test) between the test-retest scans. Mini-
mum Redundancy Maximum Relevance (mRMR) [32] feature selec-
tion with multivariable Cox-Proportional Hazards (CPH) model was
employed to identify the set of radiomic features and corresponding
CPH model that produced highest C-index for bRFS prediction on D1.
The top 5 most frequently selected radiomic features across multiple
iterations of 5-fold and 10-run cross-validation were employed to
construct the radiomic model producing a radiomic risk score (RadS)
to estimate bRFS. Moreover, a radiomic-clinicopathologic nomogram
(RadClip), integrating RadS and pre-operative PSA and biopsy GG,
was constructed based on the multivariable CPH model for 3-year
bRFS prediction. (Fig. 2) RadClip and RadS were both constructed
using the rms packages in R software version 3.6.
Validation. RadS was then evaluated on D2. Both the univariable
and multivariable CPH models were fitted with RadS and clinicopath-
ologic parameters, including biopsy GG, Prostate Imaging-Reporting
and Data System version 2 (PI-RADS v2) score [33], age, pre-operative
PSA, and clinical stage (cT, T2 or T3), to evaluate the role of radiomic
features in the prediction of bRFS after RP. A head-to-head compari-
son between RadClip, Decipher, CAPRA, and post-surgical CAPRA-S
score was conducted on subgroups of patients in D2 for bRFS predic-
tion, who either underwent Decipher test (N = 106) or had sufficient
information to calculate the CAPRA (N =106) or CAPRA-S (N = 121)
scores, in terms of concordance index (C-index) and Kaplan-Meier
curves. Both Decipher risk score, ranging 0-1, and Decipher risk
groups (low risk group with Decipher risk score < 0.4, intermediate
0.4-0.6, high > 0.6) [12] were included for comparison. Hazard ratios
(HRs) of the multivariable CPH model indicate the influence of corre-
sponding predictors. Wald test was applied and P values under .05
were considered to be statistically significant. Decision curve analysis
was adopted to calculate the net benefit for RadClip, CAPRA score
and CAPRA-S score in comparison to default strategies of treating all
or no patients [34]. Area under receiver operating characteristic curve
(AUC) was used to evaluate association between AP and pre-
Table 1
Demographic and disease characteristics of all 198 study patients.
Dataset D1Training D2Validation
Cohort CC MS UP UH DE
# patients 71 31 20 20 56
Median age, (range) 59 (47-79) 63 (48-73) 64 (49-73) 61 (47-86) 64 (42-76)
Mean pretreatment PSA§ SD, ng/mL (range) 10.0§10.9 (1 - 53.8) 8.8 § 5.0 (3.7 - 22.5) 6.0 § 1.6 (4.2 - 8.9) 10.6 § 18.5 (1.8 - 88.3) 9.0 §12.1 (1.2-69.4)
Biopsy GG, n/# patients (%)
1 15/71 (21.13) 0/31 (0) 0/20 (0) 3/20 (15) 7/56 (12.50)
2 20/71 (28.17) 15/31 (48.39) 14/20 (70) 6/20 (30) 27/56 (48.21)
3 8/71 (11.27) 9/31(29.03) 4/20 (20) 5/20 (25) 13/56 (23.21)
4 10/71 (14.08) 2/31 (6.45) 1/20 (5) 4/20 (20) 3/56 (5.36)
5 18/71 (25.35) 5/31 (16.13) 1/20 (5) 2/20 (10) 6/56 (10.71)
Pathologic GG, n/# patients (%)
1 6/71 (8.45) 0 /31 (0) 0/20 (0) 3/20 (15) 4/56 (7.14)
2 22/71 (30.99) 15/31 (48.39) 13/20 (65) 8/20 (40) 24/56 (42.86)
3 13/71 (18.31) 13/31 (41.94) 5/20 (25) 4/20 (20) 15/56 (26.79)
4 7/71 (9.86) 1 /31 (3.23) 1/20 (5) 2/20 (10) 3/56 (5.36)
5 18/71 (25.35) 2 /31 (6.45) 1/20 (5) 3/20 (15) 10/56 (17.86)
NA 5/71 (7.04)
PI-RADS v2, n/# lesions (%)
1 0/71 (0) 0/31 0/20 0/20 (00) 1/56 (1.79)
2 10/71(14.08) 0/31 0/ 20 2/20 (10) 8/56 (14.29)
3 6/71(8.45) 1/31 (3.23) 6/20 (30) 2/20 (10) 3/56 (5.36)
4 20/71(28.17) 17/31 (54.84) 8/20 (40) 6/20 (30) 10/56 (17.86)
5 34/71(47.89) 13/31 (41.94) 6/20 (30) 10/20 (50) 34/56 (60.71)
NA 1/71(1.41)
Decipher risk categories, n/# patients (%)
Low NA 16/31 (51.61) 6/20 (30) NA 23/56 (41.07)
Intermediate NA 8/31 (25.81) 8/20 (40) NA 5/56 (8.93)
High NA 7/31 (22.58) 5/20 (25) NA 28/56 (50)
NA NA 0/31 (0) 1/20 (5) NA 0/56 (0)
CAPRA, n/# patients (%)
Low NA 4/31 (12.90) NA 4/20 (20) 4/56 (7.14)
Intermediate NA 17/31 (54.84) NA 9/20 (45) 38/56 (67.86)
High NA 9/31 (29.03) NA 7/20 (35) 14/56 (25.00)
NA NA 1/31 (3.23) NA 0/20 (0) 0/56 (0)
CAPRA-S, n/# patients (%)
Low NA 11/31 (35.48) NA 4/20 (20) 16/56 (28.57)
Intermediate NA 16/31 (51.61) NA 10/20 (50) 17/56 (30.36)
High NA 4/31 (12.90) NA 5/20 (25) 20/56 (35.71)
NA NA 0/31 (0) NA 1/20 (5) 3/56 (5.36)
BCR n/# patients (%)
BCR+ 27/71 (38.03) 6/31 (19.35) 4/20 (20) 8/20 (40) 4/56 (7.14)
BCR- 44/71 (61.97) 25/31 (80.65) 16/20 (80) 12/20 (60) 52/56 (92.86)
BCR+ median follow-up / mon. 11.1 2.6 12.5 8.5 13.2
BCR- median follow-up / mon. 64.8 20.6 25 33.5 27.9
SVI, n/# patients (%)
Yes 24/71 (33.80) 4/31 (12.90) 2/20 (10) 4/20 (20) 16/67 (23.88)
No 42/71 (59.15) 27/31 (87.09) 18/20 (90) 16/20 (80) 51/67 (76.12)
Not determined 5/71 (7.04) 0/31 (0) 0/20 (0) 0/20 (0) 0/67 (0)
EPE, n/# patients (%)
Yes 33/71 (46.48) 10/31 (32.26) 10/20 (50) 8/20 (40) 42/67 (62.69)
No 30/71 (42.25) 21/31 (67.74) 10/20 (50) 12/20 (60) 25/67 (37.31)
Not determined 8/71 (11.27) 0/31 (0) 0/20 (0) 0/20 (0) 0/67 (0)
LNI, n/# patients (%)
Yes 12/71 (16.90) 3/31 (9.68) NA 1/20 (5) 20/67 (29.85)
No 41/71 (57.75) 28/31 (90.32) NA 18/20 (90) 42/67 (62.69)
Not determined 18/71 (25.35) 0/31 (0) NA 1/20 (5) 5/67 (7.46)
PSM, n/# patients (%)
Yes NA 1/31 (3.23) 19/20 (95) 6/20 (30) 33/67 (49.25)
No NA 30/31 (96.77) 0/20 (0) 14/20 (70) 34/67 (50.75)
Not determined NA 0/31 (0) 1/20 (5) 0/20 (0) 0/67 (0)
cT, n/# patients (%)
T1 NA 15/31 (48.39) 18/20 (90) 8/20 (40) 53/67 (79.10)
T2 NA 14/31 (45.16) 1/20 (5) 9/20 (45) 14/67 (20.90)
T3 NA 1/31(3.23) 1/20 (5) 3/20 (15) 0 (0)
NA 0 (0) 1/31 (3.23) 0 (0) 0 (0) 0 (0)
PSA = prostate-specific antigen, GG = Grade Group, PI-RADS v2 = Prostate Imaging Reporting and Data System version 2, BCR = Biochemical Recurrence, SVI = Seminal Vesicle
Invasion, EPE = Extra Prostatic Extension, LNI = Lymph Node Invasion, PSM = Positive Surgical Margin, cT = clinical stage, NA = Not Available.
4 L. Li et al. / EBioMedicine 63 (2021) 103163operative prognostic models RadClip, CAPRA, and Decipher on D2. We
also evaluated the association between RadClip and the presence of
SVI, EPE or LNI separately, and then compared RadClip with CAPRA,
CAPRA-S, and Decipher in terms of AUC.Role of the funding source
The sponsors of this study had no role in the research design, data
collection, data analysis, data interpretation, and paper writing. The
Table 2
MRI scan parameters.
Parameter Institution 1 Institution 2 Institution 3 Institution 4
Scanner 1 Scanner 2 Scanner 1 Scanner 1 Scanner 1










Model 3T Achieva 3T Skyra 3T Skyra 3T Skyra 3T Skyra
Coils ERC PPAC PPAC ERC PPAC
T2WI
TR/TE 38025151/105115 3730/121 5610/121 3000-6000/ 80-120 7200/96
Reconstruction voxel size (mm3) 0.3 £ 0.3 £ 3.0 0.5 £ 0.5 £ 3.0 0.3 £ 0.3 £ 3.0 0.3 £ 0.3 £ 3.0 0.6 £ 0.6 £ 3.0
Acquisition time (min) 5.36 2.53 2.54 4-5 2.25
DWI
TR/TE 35714880/5074 4700/86 8700/72 7900/88
Reconstruction voxel size (mm3) 1.4 £ 1.4 £ 3.0 1.6 £ 1.6 £ 3.0 2.2 £ 2.2 £ 3 1.4 £ 1.4 £ 3.0 1.2 £ 1.2 £ 3.0
bvalues (s/mm2) 0, 500, 1000, 1500, 2000 0, 400, 900, 1500 50,1000,1600,2000 0, 1000, 1400 50, 600, 1000, 1400
Acquisition time (min) 5.25 5.07 2.57 3-6 2.34
TR = repetition time, TE = echo time, T2WI = T2-weighted imaging, DWI = diffusion-weighted imaging, PPAC = pelvic phased-array coil, ERC = endorectal coil.
Fig. 2. overall workflow and pipeline. T2WI = T2-weighted magnetic resonance imaging; ADC = apparent diffusion coefficient.
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Table 3
Biochemical-recurrence-associated Radiomic features.
Radiomic feature Radiomic feature description
T2WI Laws feature Wave texture distribution kurtosis
T2WI Laws feature Wave-ripple texture distribution
kurtosis
T2WI intensity range Local intensity range distribution
kurtosis




ADC Laws feature Wave and edge texture distribution
kurtosis
T2WI = T2-weighted imaging, ADC = apparent diffusion coefficient.
6 L. Li et al. / EBioMedicine 63 (2021) 103163corresponding authors had full access to all data obtained from this
study and had final responsibility for the decision to submit for publi-
cation.
Results
Ability of radiomic model to predict bRFS
RadS was built with 5 radiomic features selected within D1.
(Table 3 and Fig. 3) RadS on D2 resulted in an HR = 7.01 (95% CI, 1.21
 40.68, p < .05) on multivariable analysis. RadS was significantly
associated with bRFS and found to be prognostic independent of
other pre-operative clinicopathologic parameters, including biopsy
GG, PI-RADS v2, age, pre-operative PSA, and cT, to predict bRFS.
(Table 4).
Ability of RadClip to predict bRFS and head-to-head comparisons
The prognostic performance of RadClip was validated on D2,
resulting in a HR of 1.9 (95% CI, 1.4-2.7, p < .05) and C-index of 0.77
(95% CI, 0.65-0.88). For the patients in D2, neither the Decipher risk
score (C-index 0.51, 95% CI 0.33-0.69, N=106) nor associated risk
groups (C-index 0.5, 95% CI 0.35-0.65, N=106) showed any significantFig. 3. BCR-associated Radiomic features. (a) and (c) are the bpMRI of a 59-year-old patient with BCR identified at 41-month follow-up. The patients had pathologic Gleason Gra
Group = 2, PIRADS v2 = 2, Decipher risk score = 0.52, CAPRA score = 3, CAPRA-S score = 2, no adverse pathology identified. (b) and (d) are the bpMRI of a 62-year-old patient with
BCR identified at 45-month follow-up. The patient had pathologic Gleason Grade Group = 2, PIRADS v2 = 4, Decipher risk score = 0.63, CAPRA score = 3, CAPRA-S score = 4,
adverse pathology identified. (a,b) T2WI Haralick information measures; (c,d) ADC Laws feature capturing wave-edge pattern. BCR = biochemical recurrence; bpMRI = bi-paramet
magnetic resonance imaging; PIRADS v2 = Prostate Imaging-Reporting and Data System version 2; CAPRA = Prostate Cancer Risk Assessment; CAPRA-S = Post-surgery Prostate Ca
cer Risk Assessment; T2WI = T2-weighted magnetic resonance imaging; ADC = apparent diffusion coefficient.association with bRFS in univariable analysis. (Table 5) RadClip
achieved a higher C-index than CAPRA (0.77 vs. 0.68, N=106) and a
similar C-index to CAPRA-S (0.77 vs. 0.75, N=121). (Table 3) In addi-
tion, RadClip illustrated significant association with bRFS indepen-
dent of CAPRA, CAPRA-S and Decipher in the multivariable analysis.
(Table 5) Furthermore, RadClip yielded a similar net benefit com-
pared to CAPRA and CAPRA-S across decision threshold probabilities













Biopsy GG 1.67 (1.09 -2.57) 0.79 (0.69-0.88) 0.02*
PI-RADS 0.99 (0.53-1.84) 0.97
PSA 1.04 (1.00-1.08) 0.071
Age 0.92 (0.85  0.98) 0.013*
Clinical Stage 1.92 (0.91  4..04) 0.087
RadS 7.01 (1.21  40.68) 0.03*
Table 5
Head to head comparison between RadClip, CAPRA and Decipher in BCR
prediction.
RadClip, RadS and CAPRA (N = 106,18 BCR+)




RadClip 1.9 (1.4-2.7) 0.77 (0.65-0.88) <0.001* 0.012*
CAPRA 1.4 (1.1-1.9) 0.68 (0.57-0.8) 0.007* 0.336
RadClip, RadS, and CAPRA-S (N = 121, 21 BCR+)
RadClip 2 (1.5-2.8) 0.77 (0.66-0.87) <0.001* 0.011*
CAPRA-S 1.4 (1.2-1.6) 0.75 (0.65-0.85) <0.001* 0.046*
RadClip and Decipher (N = 106, 14 BCR+)
RadClip 1.6 (1.1-2.4) 0.73 (0.59-0.87) 0.033* 0.041*
Decipher score 2.5 (0.17-37) 0.51 (0.33-0.69) 0.51 0.73
Decipher risk group 1.1 (0.61-2) 0.5 (0.35-0.65) 0.74 0.77
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We evaluated the association between RadClip and AP among
patients from the validation set with EPE, SVI, and LNI specific infor-
mation. RadClip yielded an AUC = 0.71 (95% CI, 0.62-0.81, p < .05) in
predicting AP, compared to CAPRA, AUC = 0.69 (95% CI, 0.59-0.79, p <
.05), and Decipher, AUC = 0.66 (95% CI, 0.57-0.77, p < .05), on D2. In
addition, RadClip had a higher AUC compared with CAPRA and Deci-
pher in predicting EPE, SVI and LNI (Table 6).
Discussion
The ability to predict prognosis of prostate cancer (PCa) patients
using pre-operative imaging and clinicopathologic parameters may
allow for identification of patients who are more likely to have
adverse pathologic factors, such as extracapsular extension (EPE),
seminal vesicle invasion (SVI), and lymph node involvement (LNI).
This could allow for identifying men who are not candidates for
active surveillance (AS), but rather candidates for more aggressive
treatments. Additionally, since the benefit of adjuvant radiation ther-
apy is subject to debate [35], pre-operatively identifying patients
with low risk of developing BCR after surgery could give clinicians
more confidence in deferring additional treatments in these men. In
this study, we developed a novel radiomic risk score, RadS, derived
from computerized texture features from pre-surgical bi-parametric
MRI that was shown to be independently prognostic of biochemical
recurrence free survival (bRFS). Additionally, we presented RadClip, a
pre-operative nomogram that combines radiomic features with clini-
copathologic parameters (including biopsy Gleason Grade Group and
pre-surgical PSA) to predict bRFS, as well as AP.
Results from our study indicate that Haralick features extracted
from pre-operative T2WI and Laws features derived from both T2WI
and ADC map showed significant differences between patients with
and without BCR. Haralick features [27] capture spatial intensitybased heterogeneity and Laws [26] features capture edge and wave
texture patterns on MRI. Haralick features of PCa on T2WI have been
previously shown to be associated with biochemical recurrence
(BCR) [17,29], men who had BCR following surgery tended to have a
higher expression of Haralick features within the tumor on pre-oper-
ative T2WI versus those who did not. Additionally, Laws features
derived from prostate bpMRI lesion regions have also been shown to
be associated with PCa aggressiveness, in particular with RP Gleason
grade [30]. We observed that patients with poor prognosis tended to
have higher expression of T2WI Haralick feature and edge and wave
texture within tumor regions on ADC maps, suggesting a higher
degree of morphologic disease specific heterogeneity. (Fig. 3 and
Table 3)
In our study, the performance of both CAPRA and CAPRA-S for the
task of bRFS prediction was found to be consistent to results reported
in previous studies [10]. RadClip, as a pre-operative prognostic nomo-
gram was found to outperform CAPRA score and achieve similar per-
formance as the post-surgical CAPRA-S score in a head-to-head
comparison for bRFS prediction. These results illustrated the poten-
tial of RadClip to predict prognosis pre-operatively which will allow
for identification of patients who could potentially benefit from
receiving neo-adjuvant therapy. In addition, RadClip also showed
strong association with AP, suggesting its possible utility in pre-oper-
ative identification of men with PCa who should likely be excluded
from consideration for active surveillance.
While the Decipher test has been previously validated in its ability
to predict risk of metastasis and PCa specific mortality [12,36], in our
study the test did not show a significant association with bRFS. This
may have been because the Decipher test was initially validated to
predict risk of metastasis and not BCR per se [11]. Interestingly, a pre-
vious study [36] also appeared to corroborate our findings, suggest-
ing that the Decipher risk score did not have a strong association
with post-surgical BCR. Decipher was shown to have significant asso-
ciation with AP in our validation cohort. However, note that in this
study, Decipher was performed post-surgically on the resected speci-
men, unlike RadClip which was assessed pre-operatively. Although a
previous study has suggested that Decipher estimated on biopsy tis-
sue was similar to the corresponding score estimated on the surgical
specimens [37], the biopsy sampling error may still be a concern indi-
cating by another study as no correlation between Decipher score
estimated from index lesions and benign regions [38]. Unlike Deci-
pher, RadClip is also completely tissue non-destructive and is not
constrained by the limitations of biopsy sampling errors. Also, since
RadClip only requires diagnostic mpMRI, the test does not consume
tissue like molecular tests like Decipher. We acknowledge the fact
that post-surgery Decipher test is usually reserved for patients with
T2 and positive surgical margins, T3a/b, PSA persistence, and in
selected cases of BCR; therefore, the comparison between RadClip
and Decipher may seem counter-intuitive but it reflects over-utiliza-
tion of Decipher test in this population as 45/106 patients had low
risk score.
The application of assessing the association between mpMRI
derived parameters, e.g. PI-RADS v2 score or lesion volume, with
BCR, PCa aggressiveness and molecular tests like Decipher is not new
[39,40]. Jambor et. al. illustrated that combing clinicopathologic
parameters with mpMRI was comparable in prediction of BCR as a
combination of Decipher and clinicopathologic parameters [40]. This
study was however limited in its sample size, single institutional
design and the fact that PI-RADS is known to be subject to inter-
reader variability [41]. Similarly, Shiradkar et. al. illustrated using
bpMRI derived radiomic features could be prognostic of BCR [17].
However, this study too was limited to scans from a single site in
their validation set. Our study differed from previous studies
[1720,29] in a few different ways. Firstly, instead of investigating
the correlation between radiomic features and Decipher risk catego-
ries or pathologic Gleason Grade [18], we directly built a nomogram
Fig. 4. Biochemical-recurrence-free survival analysis. (a) Kaplan-Meier survival analysis of RadClip (N = 127) with the cut-off point at 70% 3-year Biochemical-recurrence-free sur-
vival. (b) Kaplan-Meier survival analysis of Decipher score (N = 106). Decipher score > 0.6 is defined as the high risk category. (c) Kaplan-Meier survival analysis of CAPRA score
(N = 106). CAPRA score  6 is defined as the high risk. (d) Kaplan-Meier survival analysis of CAPRA-S score (N = 121). CAPRA-S score  6 is defined as the high risk. (e) 3-year bio-
chemical recurrence-free radiomic-clinicopathologic nomogram (RadClip) built with radiomic risk score (RadS), biopsy Grade Group (bGG), pre-operative prostate-specific antigen
(PSA). (f) Decision curve showing net benefit for carrying out adjuvant therapy in prostate cancer patients. It has been shown that 20-30% patients will develop BCR after RP within
10 years. Black dash line represents RadNom showing increment of the net benefit compared CAPRA score (red) and CAPRA-S score (green).
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vious approaches that have attempted to directly train radiomic clas-
sifiers against binary outcome (e.g. presence or absence of BCR)
[17,29,40], our approach employed a Cox proportional hazards
approach to build an imaging based prognostic model accounting forTable 6
Head to head comparison between RadClip, CAPRA and Decipher in Adverse Pathology pr
Model EPE, AUC (95% CI)N = 60, EPE + SVI, AUC (95% CI)N = 21, SVI +
RadClip 0.7 (0.61-0.8) 0.82 (0.74-0.91)
CAPRA 0.69 (0.59-0.79) 0.76 (0.65-0.86)
Decipher risk score 0.68 (0.58-0.78) 0.77 (0.65-0.9)time to BCR as also censoring information introduced by the variance
of follow-up time among patients. Moreover, this was also one of the
very few studies we are aware of to validate an MRI based PCa prog-
nostic tool in a multi-institutional setting [19,29,40]. The findings of
RadClip on scans from 4 institutions, suggest that the approach isediction (N = 127).
LNI, AUC (95% CI)N = 19, LNI + Adverse Pathology, AUC (95% CI)N = 66 AP +
0.77 (0.67-0.86) 0.71 (0.62-0.81)
0.74 (0.62-0.85) 0.69 (0.59-0.79)
0.73 (0.59-0.87) 0.66 (0.56-0.77)
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tions.
We acknowledge however that our study did have its limitations.
First, implicit bias may exist due to the retrospective nature of the
study; however, the multi-institutional validation suggests the
robustness of RadClip. In addition, even though 198 patients were
included in this study, this number is actually larger compared to
other recent related studies [17,18,40]. However, we acknowledge
that prior to clinical deployment, the approach needs additional ret-
rospective and potentially prospective clinical trial validation in the
future to further confirm the generalizability of our findings. Second,
this study employed BCR as a surrogate endpoint for metastasis
because of insufficient follow-up time after RP, as opposed to metas-
tasis. Furthermore, we demonstrated that the nomogram was prog-
nostic and not predictive of added benefit of neoadjuvant or adjuvant
therapy, though that it will certainly be included for our future work.
Also, an automated lesion detection and segmentation module on the
MRI scans could be implemented in consort with RadS and RadClip in
future.
In spite of these limitations, our study suggests that with addi-
tional independent multi-site validation, these radiomic features
could potentially be used for pre-operative risk stratification in
patients with PCa to allow for more effective treatment management.
Conclusion
In this study, we developed a prognostic nomogram, RadClip,
integrating radiomic features derived from pre-operative bi-
parametric MRI, biopsy GG and pre-operative PSA to predict bio-
chemical recurrence free survival and adverse pathology in prostate
cancer patients undergoing prostatectomy. RadClip outperformed
Decipher risk score and CAPRA score on a limited hold-out validation
set.
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